Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
- Pushing The Boundaries In Cell Therapy: CAR-T Updates From EHA 2025
- Inside AviadoBio And Astellas's Shared Mission To Bring Gene Therapy To Patients With FTD-GRN
- Cleaning Process Capability: Risk-Based Cleaning Process Performance Qualification
- How CGT Leaders Are Reducing Failures, Scaling Processes, And Overcoming Regulatory Friction
- Why 'Which Is Best?' Is The Wrong Question In CGT Development
- Understanding FDA's New National Priority Voucher Pilot Program
- The Latest Techniques And Technology For Differentiating Capsids
- Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Direct And Rapid Multi-Attribute Monitoring Of Intact Monoclonal Antibodies By icIEF-UV/MS
Explore a novel integrated workflow and system that offers direct chip-based integration of imaged capillary isoelectric focusing (icIEF) with mass spectrometry (MS).
-
Addressing The Challenges In Lentivirus Harvest Clarification
Traditional depth filtration struggles with lentiviral harvest clarification, leading to low yields and high costs. However, single-use centrifugation offers a promising alternative.
-
EHR-To-EDC Success In A Complex, Adaptive Platform Trial
I-SPY 2, one of the longest-running adaptive platform trials in oncology, is revolutionizing breast cancer research through a dynamic, data-driven approach to evaluating novel therapies.
-
Development Of Endothelial-Cord Cell Banks And Blood Stem Cell Products
Leverage our proven cGMP expertise in cell therapy manufacturing, from primary tissue processing to large-scale production for clinical trials.
-
Studying The Spatial Architecture Of Glioblastoma
Explore how intra-tumor heterogeneity (ITH) impacts cancer progression and therapy resistance with advanced imaging platforms and custom antibody panels to reveal the spatial architecture of glioblastoma (GBM).
-
A Hybrid Modeling Approach To Accelerate Media And Feed Development
Explore the outcomes of a study focusing on building a mechanistic model to determine the growth kinetics of a CHO-based process producing a mAb.
-
Rapid, Automated, At-Line Adenovirus Quantitation
Gain insight into how a high-throughput capsid assay for rapid AV quantification was developed using an innovative Bio-Layer Interferometry (BLI) platform that offers high precision and reliability.
-
The Rescue Option: Course Correcting Struggling Clinical Trials
The willingness to seek expert support from Rescue CROs when clinical trials face critical challenges is not a sign of weakness but a demonstration of accountability and commitment to excellence.
-
Optimizing TFF And SPTFF For High-Concentration mAb Formulations
Discover the critical role of formulation buffer composition in stabilizing monoclonal antibodies during tangential flow filtration, a process involving ultrafiltration and diafiltration under high pressure and shear forces.
-
UpTempo Plasmid DNA Platform
Gain insight into these end-to-end plasmid DNA solutions, leveraging robust cGMP-compliant processes and single-use manufacturing platforms to accelerate your cell and gene therapy programs.
NEWSLETTER ARCHIVE
- 07.03.25 -- New Podcast Episodes: Microbes, CGT Development, & FDA Engagement in Focus
- 07.03.25 -- Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More
- 07.02.25 -- Hope For People With Spinocerebellar Ataxia
- 07.01.25 -- STREAM Edition: De-Risk Your Path To Clinic With An AAV Suspension Platform
- 07.01.25 -- Closed-Loop Manufacturing Is The Cell Therapy Revolution We Need

- Inside AviadoBio And Astellas's Shared Mission To Bring Gene Therapy To Patients With FTD-GRN
- Advancing Gene Delivery: LNPs, Adenovirus, Lentivirus, And More
- Rethinking Academic Translation In CGT: Inside The RISE Framework At Mass General Brigham
- The Promise Of Focused Ultrasound For AAV Gene Therapy Delivery
- Unlocking The Potential Of iPSC Therapies In Regenerative Medicine
CELL AND GENE CONTENT COLLECTIONS

While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections